Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors
Research Project
|
01.07.2022
- 30.06.2024
Laufzeit 01.04.2022-31.01.2024 Increased activity of mammalian target of rapamycin complex 1(mTORC1) is linked to multiple disorders. We identified ten small compounds that selectively and efficiently inhibit mTORC1 in vitro with an innovative mode of action. We now aim to achieve precinlincal proof of mechanism in mice.
Funding
Preclinical in vivo proof of mechanism study of selective mTORC1 inhibitors
Innosuisse Projekt (GrantsTool), 07.2022-06.2024 (24)